Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?

DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
Open original source
DHR's Biotechnology segment posts 7% core revenue growth as bioprocessing demand stayed strong and equipment orders jumped despite headwinds.
Open original source